ALL ORDERS MUST BE SIGNED, DATED AND TIMED BY PHYSICIAN					
lergies/Reactions:		066	☐ Gig Harbor Infusion Services - Fax: 253-530-8069		
	☐ Allenmore Ambulatory Infusion Services - F	Fax: 253-864-4052	☐ DHEC Infusion Center	er - Fax: 509-755-5845	
	☐ Auburn Infusion Services - Fax: 253-876-8		<u> </u>	sion Center - Fax: 509-232-2531	
ORDERS WITH CHECK BOXES When an order is optional (those with check boxes), physicians are responsible for indicating a check mark in the box next to the order. Orders left unchecked will not be initiated.					
Canakinumab (Ilaris):					
Patient Name:		_Requested Do	ate of Service:	/	
Date of Birth:/ Patient Phone Number: () ¬ May leave message					
		ICD -10 Code	<u>\$</u> :		
Diagnosis: ☐ Adult Onset Still's Disease					
Periodic fever syndromes					
☐ Cryopyrin-Associated Periodic Syndromes (CAPS)					
☐ TNF Receptor Associated Periodic Syndrome (TRAPS)					
☐ Hyperimmunoglobulin D Syndrome (HIDS)			D		
■ Mevalonate Kinase Deficiency (MKD)					
☐ Familial Mediterranean Fever (FMF)					
☐ Other					
Required: H&P with documentation to support above diagnosis including ICD-10 code and supporting labs **If required documentation not received with order, scheduling of treatment will be delayed until complete information is available**					
☑ Reason patient not able to self-ad	minister medication:				
Baseline Labs Required: • Latent TB testing Date:/ Results:					
Contact provider if patient develops serious infection; close monitoring by provider is recommended. Follow-up appointment with					
referring provider scheduled for (date):/					
Treatment Regimens: ☐ Adult Onset Still's Disease: 4 mg/kg SQ every 4 weeks (MAX 300 mg/dose) ☐ CAPS: ☐ >40 kg: 150 mg SQ every 8 weeks OR ☐ 15 to 40 kg: 2 mg/kg SQ every 8 weeks ☐ MKD, TRAPS, FMF, HIDS: ☐ >40 kg: 150 mg SQ every 4 weeks OR ☐ 2 mg/kg SQ every 4 weeks					
☑ Vital signs: Check vital signs prior to and at completion of dose. Contact provider if systolic BP>180; diastolic BP>100; systolic BP<90; HR >110; temp >38C (100.4F)					
 If Hypersensitivity reaction (fever, chills, hypotension, rigors, itching, rash, etc.) Consult MultiCare hypersensitivity guideline for treatment management Notify provider of reaction, assessment and need for further orders 					
Code Status: Please note, patients will be considered FULL Code unless marked otherwise. If the patient has a POLST, advance directive or living will, please include a copy with the orders.					
Was consent obtained: ☐ Yes ☐ No (if yes, please send DOCUMENTATION of consent with order)					
Provider Signature	Print Name		Date	Time	
Another brand of drug, identical in form and content, may be dispensed unless checked Orders expires in 12 months**					

Patient Identification - Always Attach Patient Label

Name:

MRN #:

CSN #:

Age / Sex and Gender:

Pre-printed Order

CANAKINUMAB (Ilaris)

MultiCare 🕰

